What this means
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
A plain-English summary is on its way. Until then, this is the start of the registry's own summary.
- Status
- Active not recruiting
- Who can join
- Ages 60–85
- Where
- 3 sites
The science
- Registered title
- Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
- Trial ID
- NCT06984094 ↗
- Phase
- PHASE 1 / PHASE 2
- Study type
- interventional
- Conditions
- RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- What is tested
- SCB-1019T, SCB-1022, SCB-1033, Placebo (saline)
- Sponsor
- Clover Biopharmaceuticals AUS Pty
- Ages
- 60 Years to 85 Years
- Dates
- First posted May 22, 2025 · updated Oct 26, 2026
Registry summary
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
Sites (3)
- Fusion Clinical Research, Adelaide, Southern Australia, Australia
- Paratus Clinical Research, Melbourne, Victoria, Australia
- Linear Clinical Research, Perth, Western Australia, Australia